205 related articles for article (PubMed ID: 27141101)
1. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
[No Abstract] [Full Text] [Related]
4. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
Pan D; Kocherginsky M; Conzen SD
Cancer Res; 2011 Oct; 71(20):6360-70. PubMed ID: 21868756
[TBL] [Abstract][Full Text] [Related]
5. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
6. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
Prekovic S; Chalkiadakis T; Roest M; Roden D; Lutz C; Schuurman K; Opdam M; Hoekman L; Abbott N; Tesselaar T; Wajahat M; Dwyer AR; Mayayo-Peralta I; Gomez G; Altelaar M; Beijersbergen R; Győrffy B; Young L; Linn S; Jonkers J; Tilley W; Hickey T; Vareslija D; Swarbrick A; Zwart W
EMBO Mol Med; 2023 Dec; 15(12):e17737. PubMed ID: 37902007
[TBL] [Abstract][Full Text] [Related]
7. Reprogramming the chromatin landscape: interplay of the estrogen and glucocorticoid receptors at the genomic level.
Miranda TB; Voss TC; Sung MH; Baek S; John S; Hawkins M; Grøntved L; Schiltz RL; Hager GL
Cancer Res; 2013 Aug; 73(16):5130-9. PubMed ID: 23803465
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells.
Courtin A; Communal L; Vilasco M; Cimino D; Mourra N; de Bortoli M; Taverna D; Faussat AM; Chaouat M; Forgez P; Gompel A
Breast Cancer Res Treat; 2012 Jan; 131(1):49-63. PubMed ID: 21336598
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer.
Buxant F; Engohan-Aloghe C; Noël JC
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):254-7. PubMed ID: 19875955
[TBL] [Abstract][Full Text] [Related]
10. The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.
Ogara MF; Rodríguez-Seguí SA; Marini M; Nacht AS; Stortz M; Levi V; Presman DM; Vicent GP; Pecci A
Nucleic Acids Res; 2019 Nov; 47(20):10645-10661. PubMed ID: 31598691
[TBL] [Abstract][Full Text] [Related]
11. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
12. Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells.
Rocha W; Sanchez R; Deschênes J; Auger A; Hébert E; White JH; Mader S
Mol Pharmacol; 2005 Dec; 68(6):1852-62. PubMed ID: 16186250
[TBL] [Abstract][Full Text] [Related]
13. Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition.
Kinyamu HK; Collins JB; Grissom SF; Hebbar PB; Archer TK
Mol Carcinog; 2008 Nov; 47(11):845-85. PubMed ID: 18381591
[TBL] [Abstract][Full Text] [Related]
14. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
15. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer.
Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers.
Shi W; Wang D; Yuan X; Liu Y; Guo X; Li J; Song J
J Mol Cell Biol; 2019 Dec; 11(12):1042-1055. PubMed ID: 30726932
[TBL] [Abstract][Full Text] [Related]
17. Regulation of prothymosin alpha gene expression by estrogen in estrogen receptor-containing breast cancer cells via upstream half-palindromic estrogen response element motifs.
Martini PG; Katzenellenbogen BS
Endocrinology; 2001 Aug; 142(8):3493-501. PubMed ID: 11459795
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
[TBL] [Abstract][Full Text] [Related]
19. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
20. Coactivation of Estrogen Receptor and IKKβ Induces a Dormant Metastatic Phenotype in ER-Positive Breast Cancer.
El-Shennawy L; Dubrovskyi O; Kastrati I; Danes JM; Zhang Y; Whiteley HE; Creighton CJ; Frasor J
Cancer Res; 2018 Feb; 78(4):974-984. PubMed ID: 29229606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
